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Angiotensin-converting enzyme gene polymorphism in non-insulin de-
pendent diabetes mellitus and its relationship with diabetic nephropathy.
Previous studies have shown that the angiotensin-converting enzyme
(ACE) gene polymorphism is associated with an increased risk of vascular
disease in non-diabetic patients. The present study was conducted on 509
NIDDM patients who underwent a screening test to determine their ACE
genotype for the Appropriate Blood Pressure Control in Diabetes
(ABCD) Trial. Various baseline indices were correlated with the three
ACE polymorphisms. The genotype was determined through polymerase
chain reaction amplification of the angiotensin-converting enzyme poly-
morphism. The univariate relationship between the presence of the DD
genotype with nephropathy as measured by urinary albumin excretion
(UAE), and a history coronary artery disease (CAD) was then examined.
Finally, a multiple model for each UAE and CAD was created so as to
determine the independent effects of the presence of the DD genotype on
each diabetic complication. Univariately, the presence of the DD geno-
type was associated with diabetic nephropathy. Furthermore, in a multiple
model predicting diabetic nephropathy, the presence of the DD genotype
was independently associated with diabetic nephropathy (odds ratio = 2.8,
95% confidence interval 1.4 to 5.5) but not CAD. Thus, the ACE DD
genotype in 509 non-Hispanic white NIDDM patients in a metropolitan
area in the U.S. was independently associated with the presence of
diabetic nephropathy and, therefore, may be potentially used as a marker
for NIDDM patients at risk for developing diabetic nephropathy.
Non-insulin dependent diabetes mellitus (NIDDM) accounts
for approximately 90% of the 14 million diabetic patients in this
country [1], Moreover, this disease is responsible for over 90
billion dollars in annual health costs in the United States [2].
Diabetic nephropathy is the most frequent cause of end-stage
renal disease (ESRD) in the United States, accounting for 33% of
all cases. This complication costs the United States health system
three billion dollars annually [3]. Insulin-dependent diabetes
mellitus (IDDM) is estimated to account for 40%, while NIDDM
diabetes causes 60% of the ESRD secondary to diabetic nephrop-
athy. Prior studies have shown that the renin-angiotensin system
may play an important role in the development of nephropathy
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and other diabetic complications in NIDDM [4], and thus the
angiotensin-converting enzyme (ACE) polymorphism may be a
potential predictor of NIDDM complications. The polymorphism
consists of the presence (I allele) or absence (D allele) of a 287 bp
alu repeat sequence, and the D allele is associated with higher
serum ACE activity [5—7].
Previous studies in non-diabetic subjects have demonstrated
that the presence of the DD genotype was associated with an
increased risk for myocardial infarction [8] and dilated cardiomy-
opathy [SI. In NIDDM patients there are conflicting results
regarding the relationship between the ACE genotype and dia-
betic complications. Fujisawa et al showed that expression of the
DD genotype is related to myocardial infarction but not to
diabetic nephropathy or retinopathy in 267 Japanese NIDDM
subjects [10]. On the other hand Mizuiri et al, in 111 Japanese
NIDDM subjects, showed that the II genotype was associated with
a decreased risk of diabetic nephropathy [11]. To date there have
been no studies performed in the U.S. evaluating the effects of the
ACE genotype on NIDDM subjects.
The present study was therefore conducted on 509 non-His-
panic NIDDM patients who underwent a screening test to deter-
mine their ACE genotype for the Appropriate Blood Pressure
Control in Diabetes (ABCD) Trial [12]. In these patients the
study examined baseline characteristics across the three ACE
genotypes as well as the effects of genotype on coronary artery
disease and diabetic nephropathy in multiple models.
METHODS
Study population
The Appropriate Blood Pressure Control in Diabetes (ABCD)
Trial is a randomized, prospective, blinded clinical trial designed
to determine the effects of moderate versus intensive antihyper-
tensive control on the outcome of diabetic complications. The
ABCD trial has been described previously [13]. Subjects in the
ABCD Trial were between the ages of 40 and 74 years and were
identified from Diagnosis Related Group (DRG), pharmacy and
billing lists from participating hospitals from March 1991 through
January 1993. All patients enrolled in the ABCD Trial were
diagnosed with NIDDM according to the criteria based upon the
World Health Organization report of 1985 [14], which followed
the National Diabetes Group criteria of 1979 [1].
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Six hundred ninety-seven NIDDM subjects had their angioten-
sin-converting enzyme insertion/deletion polymorphism deter-
mined in a single lab at the University of Colorado Health
Sciences Center (Denver, CO, USA). Because of the smaller
number of the other racial and ethnic groups, the study evaluated
only the non-Hispanic white subjects. Informed consent was
obtained on all patients. Accordingly, we determined the distri-
bution frequency of angiotensin-converting enzyme insertion/
deletion (I/D) polymorphism.
Genomic DNA preparation
Genomic DNA was extracted from peripheral blood as de-
scribed previously [101. Briefly, genomic DNA was extracted from
leukocytes in dried blood spots collected on filter paper. Spots
were excised using sterile biopsy punches, placed into microfuge
tubes, and incubated at 56°C for 18 hours in lysis buffer (154 m'vi
NaCI, 10 mti Tris-HC1 pH 7.5, 1 m'vi NaEDTA, pH 8.0, 5%
proteinase K, 1% SDS). Proteins were removed by sequential
phenol-chloroform and chloroform extraction. DNA was precip-
itated from the aqueous phase by addition of 1/10 volume 3M
sodium acetate (pH 5.0) and an equal volume of ice-cold isopro-
panol. Samples were held at —20°C overnight, and genomic DNA
was collected by centrifugation.
Polymerase chain reaction amplification of the
ACE polymorphism
The polymorphic region of the angiotensin-converting enzyme
intron 16, consisting of the presence (I) or absence (D) of a 287 bp
alu repeat sequence, was amplified from genomic DNA by
polymerase chain reaction (PCR). The oligonucleotide primers
used in the reaction were as previously published [4, 5]. Approx-
imately 500 ng to 1 jg of genomic DNA was used per reaction,
and the reaction conditions were as previously published [10]. The
ACE genotype of each study participant was scored based on
resolution of PCR products by gel electrophoresis. Amplification
of the D allele resulted in a 190 bp DNA fragment and amplifi-
cation of the I allele resulted in a 490 bp fragment. Homozygotes
had a single 190 (DD) or 490 (II) bp band; heterozygotes had one
190 bp and one 490 bp band. Random replication of PCR
amplification was used to verify all of the results.
Assessment of blood pressure
Blood pressure measurements were taken 8 to 11 weeks after
the cessation of pre-existing antihypertensive medications during
the pre-randomization placebo run-in period. Three blood pres-
sure measurements were taken two minutes apart in the sitting
position using a standard mercury sphygniomanometer at the
randomization visit. The mean of these three measurements was
used for analysis. Diastolic blood pressure was defined as the
disappearance of the last Korotkoff sound and systolic blood
pressure was defined as the first Korotkoff sound. All study nurses
passed a standardized examination and were certified annually in
the methods of obtaining proper blood pressure measurements by
Shared Care, Inc. The recommendations for obtaining blood
pressure measurements made by the American Heart Association
(AHA) were used in the conduct of the ABCD Trial.
Assessment of metabolic parameters
Plasma glucose was measured in the fasting state and analyzed
by a hexokinase enzyme reagent using an autoanalyzer (normal
range 65 to 115 mg/dl; Olympus AU 5000; Olympus AU, Inc.,
Lake Success, NY, USA). Glycosylated hemoglobin was measured
by affinity chromatography (normal range 5.5 to 8.2%; Helenda
Labs, Beaumont, TX, USA) [15]. All lipid analyses were per-
formed by a laboratory certified by the Cholesterol Reference
Method Laboratory Network. Triglycerides were measured using
the lip ase glycerol phosphate oxidase method (Olympus AU 5000)
[16]. Total cholesterol was measured using the cholesterol oxi-
dase/hydrogen peroxide method [17J. HDL cholesterol was mea-
sured using a high performance enzymatic method (Sigma Diag-
nostics, St. Louis, MO, USA) [18].
Assessment of coronary artery disease
For purposes of statistical analyses, coronary artery disease
(CAD) was considered to be present if a past history of myocar-
dial infarction, positive cardiac catheterization results, percutane-
ous transluminal coronary angioplasty and/or coronary artery
bypass surgery was noted. For participants who indicated that they
had experienced one or more of these events, all efforts were
made to obtain medical records.
Assessment of urinary albumin excretion/nephropathy
Urinary albumin excretion (UAE) was measured for individual
patients on three separate occasions consisting of one 24-hour
urine collection and two overnight collections. Patients were
instructed to avoid strenuous exercise before providing urine
samples. Urine albumin concentrations were measured within ten
days of storage at standard refrigerator temperature. During the
first eight months of the study UAE was measured by the
nephelometric method [19], which has a sensitivity of 2 mg/dl, and
thereafter UAE was measured using radioimmunoassay (Double
Antibody Albumin #KHAD2; Diagnostic Products Corp., Los
Angeles, CA, USA), which has a sensitivity of 0.3 mg/dl and an
interassay coefficient of variation of 3%. The correlation coeffi-
cient for the two methods was r2 = 0.99 (N = 68). For this study,
the definition of diabetic nephropathy or overt albuminuria was
an UAE measurement 200 ig/min.
Definitions
Hypertension was defined as a mean sitting diastolic blood
pressure (DBP) 90 mm Hg and/or systolic blood pressure (SBP)
 140 mm Hg. Duration of diabetes and hypertension were
defined by personal history as the period between diagnosis of
these disorders and the age at the time of the baseline examina-
tion. Minimal waist/maximal hip ratio was defined as the mini-
mum circumference at or below the iliac crest. Body mass index
(BMI) was calculated as weight/height2 (kg/m2).
Statistics
The Statistical Analysis Software (SAS) system was used for all
statistical analyses. When searching for differences in baseline
characteristics across the three levels of genotype, two statistical
procedures were used. When the baseline characteristic was
continuous (age, duration of diabetes, SBP, DBP, duration of
hypertension, glycosylated hemoglobin, glucose, serum creatinine,
height, weight, BMI, cholesterol, HDL, uric acid and pack years
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Table 1. Baseline characteristics of the ABCD Trial population
according to ACE genotype
Variable
IT
(N = 162)
ID
(N 238)
DD
(N 109)
Gender male/female 103/59 157/81 65/44
Age years 57.8 0.8 59.1 0.5 58.9 0.7
Duration of diabetes years 8.7 0.7 8.5 0.5 8.8 0.6
Systolic blood pressure mm Hg 143.7 1.8 145.9 1.2 144.0 1.4
Diastolic blood pressure mm Hg 89.6 0.7 90.3 0.6 90.2 0.6
Duration of hypertension years 9.1 1.0 10.1 0.7 9.9 0.8
Glycosolated hemoglobin % 11.3 0.3 11.2 0.2 11.5 0.2
Fasting glucose mg/dl 187.4 6.6 190.7 4.3 194.3 5.3
Serum creatinine mg/dl 1.1 0.1 1.1 0.1 1.1 0.02
BMI kg/m2 31.8 0.6 31.7 0.4 31.7 0.4
Cholesterol mg/dl 215.1 3.6 212.1 2.4 218.4 3.7
HDL mg/dl 40.2 1.2 39.5 0.7 40.2 0.9
Triglyceride mg/dl 253.3 23.6 266.2 16.0 282.9 19.3
Uric acid mg/dl 5.5 0.1 5.7 0.1 5.6 0.1
Pack years smoking 18.2 2.6 21.6 2.0 24.0 2.6
All values are reported as means standard errors.
* Conversion factors for expressing conventional units in Système
Internal (SI) units: fasting glucose, mg/dl >< 0.0555 1 = mmol/liter; serum
creatinine, mg/dl >< 88.4 = .rmol/1iter; cholesterol/HDL, mg/dl x
0.02586 = mmol/liter; uric acid, mg/dl x 59.48 = jrmol/liter.
smoking) an analysis of variance (ANOVA) was used. Chi-square
analyses were used when the baseline characteristics were cate-
gorical (gender and race/ethnicity). A Chi-square analysis was also
used for analyzing contingency tables exploring the univariate
relationship between the genotype and each diabetic complication
(diabetic nephropathy and coronaly artery disease). Multiple
logistic regression was employed when evaluating the effect(s) of
a continuous and/or categorical covariate(s) on each diabetic
complication. Odds ratios and their corresponding confidence
intervals were then calculated from the logistic regression param-
eter estimates. When the outcome variable was clearly non-
normally distributed, nonparametric analyses or parametric anal-
yses on a suitably transformed variable were performed.
RESULTS
Baseline characteristics
The distribution of the l/D polymorphism is reported in Table
1. Baseline characteristics were compared across all three geno-
types (Table 1). This table shows that these baseline characteris-
tics were similar for the three different genotypes.
Coronary artery disease
Univariately, a Chi-square test revealed that there was no
association between genotype and coronary artery disease (P =
0.23). Specifically, 54 (33%) of the patients with the DD genotype
had coronary artery disease whereas 135 (39%) of the patients
with the ID or II genotype had coronary artery disease.
Results of fitting the stepwise logistic regression model for
coronary artery disease are presented in Table 2. Variables that
are independently associated with coronary artery disease are age
(OR = 1.2 per 5-year increase, 95% Cl. 1.1 to 1.4), duration of
diabetes (OR = 1.5 per 10-year increase, 95% CI. 1.1 to 2.0) and
HDL [OR = 0.9 per 5 mg/dl (0.1293 mmol/liter) increase, 95%
C.I. 0.8 to 1.0]. The presence of the DD genotype (OR =0.8,95%
C.I. 0.5 to 0.2) was not statistically associated with coronary artery
disease (P 0.56),
Table 2. Logistic regression model for cardiovascular disease
Variable Odds ratio 95% CI. P value
Change for
continuous
variables
Age 1.232 1.091—1.390 0.0008 5 years
Duration of 1.511 1.149—1.986 0.0031 10 years
diabetes
HDL 0.912 0.832—0.999 0.0484 5 mg/dl
(0. 1293
mmol/liter)
Presence of DD 0.782 0.5 18—1.181 0.2426
genotype
Table 3. Relationship between genotype and diabetic nephropathy
Diabetic nephropathy
Genotype
TotalDD ID or II
Present
Absent
23
(14.2%)
139
(85.8%)
27
(7.8%)
320
(92.2%)
50
459
Total 162 347 509
The Chi-square test was statistically significant (P = 0.023).
Table 4. Logistic regression model for diabetic nephropathy
Variable Odds ratio 95% C.I. P value
Change for
continuous
variables
Systolic blood 1.476 1.225—1.778 0.0001 10 mm Hg
pressure
Uric acid 1.617 1.270—2.059 0.0001 1 mg/dl
(59.48 j.Lmol/liter)
Pack years smoking 1.127 1.030—1.232 0.0088 10 years
HDL 0.799 0.662—0.963 0.0187
Duration of 2.216 1.446—3.394 0.0003 10 years
diabetes
Presence of DD 2.787 1.403—5.533 0.0034
genotype
Diabetic nephropathy (overt albuminuria)
Initially, we performed the univariate analysis using DD, ID,
and II genotypes as separate categories of the ACE polymor-
phism. The results revealed that 14.20% of the DD, 8.40% of the
ID, and 6.42% of the II had overt albuminuria with a of P =
0.065. We then used the ACE polymorphism as a dichotomous
variable comparing the DD genotype versus the Il/ID genotypes.
Univariately, the Chi-square test revealed that there is an associ-
ation between genotype and diabetic nephropathy (P = 0.023),
which is demonstrated in Table 3.
Results of fitting the stepwise logistic regression model for
diabetic nephropathy are presented in Table 4. The presence of
the DD genotype (OR 2.8, 95% CI. 1.4 to 5.5) appeared to
have the strongest association with diabetic nephropathy.
DISCUSSION
As the age of the U.S. population increases, so will the number
of newly diagnosed NIDDM patients [20]. These patients and
their complications will undoubtedly place a further burden on
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the already stressed healthcare system in our country. In the
present study, we evaluated the relationship of the ACE geno-
types with diabetic nephropathy and coronary artery disease in
509 non-Hispanic white NIDDM patients. The results revealed
that expression of the DD genotype is independently associated
with an increased risk for diabetic nephropathy but was not
associated with coronary artery disease.
In previous studies, there have been conflicting data regarding
the association between the ACE gene polymorphism and cardio-
vascular disease in the diabetic and non-diabetic populations [9,
10, 21—25]. In a study with NIDDM subjects, Ruiz et a! demon-
strated an increasing relative risk in individuals heterozygous and
homozygous for the D allele with regard to the presence of
coronary artery disease [25]. Contrary to Ruiz's findings, the
results of the present study revealed no association between the
ACE genotype and coronary artery disease. Since the present
study subjects were obtained from the ongoing ABCD Trial, the
inclusion criteria of a diastolic blood pressure  80 mm Hg
selected a population with a relatively high baseline blood pres-
sure (145/9 1 mm Hg). Thus, the combination of hypertension and
NIDDM in the present study population may overshadow the
ACE genotype's effect on coronary artery disease for the present
study.
We found an independent association between the DD geno-
type and the development of overt albuminuria. This association
suggests that the angiotensin-converting enzyme polymorphism
may be an important marker in the development of diabetic
nephropathy in NIDDM. As such, patients with the DD genotype
are more likely to develop diabetic nephropathy as compared to
patients with the ID or H genotype independent of the effects of
other known or suspected risk factors. Perhaps due to racial
differences, the present finding is not consistent with the results of
Fujisawa et al in Japanese diabetic patients [10], but is compatible
with the results of another study suggesting that the presence of
the D allele may increase the risk of diabetic nephropathy in
IDDM [4]. In a study reported by Doria et at that evaluated the
role of the ACE genotype in 151 IDDM subjects, the DD allele
demonstrated a trend toward the presence of diabetic nephropa-
thy but was not statistically significant (OR = 2.0, 95% C.I. 0.8 to
4.9) [26]. Schmidt et at evaluated 247 IDDM and 455 NIDDM
patients with a diabetes duration of greater than 10 years [27] that
revealed no association between the ACE genotype and diabetic
nephropathy. However, the diagnosis of diabetic nephropathy was
a UAE measurement >20 j.tg/min in this previous study; the
definition of diabetic nephropathy in our study was overt albu-
minuria, that is, UAE >200 sg/min. When we performed the
analysis using the same definition of diabetic nephropathy as the
study by Schmidt et at, we obtained a similar non-significant
association between ACE genotype and diabetic nephropathy.
Thus, in the present NIDDM population the DD genotype is
independently associated with overt albuminuria. The other risk
factors found to be associated with diabetic nephropathy in the
present study included an elevated SBP, elevated uric acid, and an
increased duration of diabetes. These are similar risk factors
found in earlier studies [28—301. It should also be noted that this
study population was generally in poor control with a mean
glycosylated hemoglobin of 11.3%, and thus the effects of the DD
genotype may be more pronounced in a NIDDM population with
poorer glucose control.
Previous research has demonstrated that patients with the DD
genotype have higher serum ACE activity than patients with the
ID and II genotypes [4, 5]. Since ACE activity plays an important
role in the renin-angiotensin and kallikrein-kinin systems in
regulating systemic blood pressure, water balance and renal
hemodynamics, increased ACE activity associated with the DD
genotype in NIDDM patients may promote alterations in renal
hemodynamics that can contribute to increased intraglomerular
pressure and hyperfiltration [31, 32]. These alterations in turn may
contribute to the development and progression of diabetic ne-
phropathy.
Lastly, results of the present study may have an impact on the
management of diabetic nephropathy, currently the most common
cause of end-stage renal disease (ESRD) in this country. More-
over, nearly 50% of all new ESRD patients have diabetic ne-
phropathy. The present results suggest that NIDDM patients with
the DD genotype, especially in combination with the other known
risk factors, are at higher risk for diabetic nephropathy. These
NIDDM patients therefore warrant close follow-up, and perhaps
when microalbuminuria is present to initiate ACE inhibitors. On
the background of this information, interventional studies such as
the ABCD Trial are needed to determine efficacious interventions
for these NIDDM patients.
Dr. Robert W. Schrier, Division of Renal Diseases and Hypertension,
Department of Medicine, Universiiy of Colorado Health Sciences Center,
4200 E. Ninth Ave., #BJ 78, Denver, Colorado 80262, USA.
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